Position in PTGX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,741,739
+$710,927 QoQ
Shares Held
14,209
+45.3% QoQ
Ownership
0.022%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#151
of 341 holders
Holding Since
Sep 2024
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PTGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Weiss Asset Management LP holds $396,341,883 across 27 Biotechnology names. PTGX ranks #16 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TBPH |
Theravance Biopharma, Inc.
|
7,457,060 | $126,770,020 | |
| 2 | ROIV |
Roivant Sciences Ltd.
|
2,542,652 | $89,984,454 | |
| 3 | MLTX |
MoonLake Immunotherapeutics
|
2,581,813 | $50,267,899 | |
| 4 | BBIO |
BridgeBio Pharma, Inc.
|
320,184 | $23,847,304 | |
| 5 | TGTX |
Tg Therapeutics, Inc.
|
375,082 | $20,607,005 | |
| 6 | AXSM |
Axsome Therapeutics, Inc.
|
80,000 | $19,581,600 | |
| 7 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
134,014 | $10,923,481 | |
| 8 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
19,325 | $10,376,558 |
All Filings in PTGX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,741,739 | 14,209 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $1,030,812 | 9,780 | Shares | Defined | 2026-05-15 | |
| 2025-09-30 | $950,613 | 14,310 | Shares | Defined | 2025-11-14 | |
| 2024-09-30 | $2,810,835 | 62,463 | Shares | Defined | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||